According to Zacks, “Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company’s product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States. “
Other analysts have also recently issued reports about the company. Nomura reiterated a buy rating and issued a $16.00 price objective on shares of TapImmune in a research note on Tuesday, August 13th. Oppenheimer initiated coverage on TapImmune in a research note on Wednesday, July 3rd. They issued an outperform rating and a $15.00 price objective on the stock. Janney Montgomery Scott reiterated a buy rating on shares of TapImmune in a research note on Sunday, July 21st. Finally, ValuEngine upgraded TapImmune from a hold rating to a buy rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and an average target price of $10.21.
TapImmune (NASDAQ:MRKR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. On average, analysts expect that TapImmune will post -0.51 EPS for the current year.
In other TapImmune news, insider Peter L. Hoang purchased 10,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $4.62 per share, for a total transaction of $46,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 23.70% of the stock is owned by company insiders.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Further Reading: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.